146 related articles for article (PubMed ID: 21183763)
1. A randomized pilot trial for aggressive therapeutic approaches in aspirin-resistant patients undergoing percutaneous coronary intervention.
El-Atat F; Sarkar K; Kodali V; Karajgikar R; Jakkulla M; Mares A; Sharma S; Kini A
J Invasive Cardiol; 2011 Jan; 23(1):9-13. PubMed ID: 21183763
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
[TBL] [Abstract][Full Text] [Related]
3. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
Moliterno DJ;
Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
[TBL] [Abstract][Full Text] [Related]
4. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
[TBL] [Abstract][Full Text] [Related]
5. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
6. Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
Sheikh-Taha M; Ghosn S
J Pharm Pract; 2012 Oct; 25(5):537-40. PubMed ID: 22572222
[TBL] [Abstract][Full Text] [Related]
7. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Feldman DN; Wong SC; Bergman G; Minutello RM
J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
[TBL] [Abstract][Full Text] [Related]
8. The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
Saw J; Densem C; Walsh S; Jokhi P; Starovoytov A; Fox R; Wong G; Buller C; Ricci D; Mancini GB; Fung A
JACC Cardiovasc Interv; 2008 Dec; 1(6):654-9. PubMed ID: 19463380
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
[TBL] [Abstract][Full Text] [Related]
10. Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial.
Madhavan MV; Généreux P; Kirtane AJ; Xu K; Witzenbichler B; Mehran R; Stone GW
Eur Heart J Acute Cardiovasc Care; 2017 Oct; 6(7):650-658. PubMed ID: 26124455
[TBL] [Abstract][Full Text] [Related]
11. Bivalirudin during primary PCI in acute myocardial infarction.
Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
[TBL] [Abstract][Full Text] [Related]
12. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
[TBL] [Abstract][Full Text] [Related]
14. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
Exaire JE; Butman SM; Ebrahimi R; Kleiman NS; Harrington RA; Schweiger MJ; Bittl JA; Wolski K; Topol EJ; Lincoff AM;
Am Heart J; 2006 Jul; 152(1):157-63. PubMed ID: 16824849
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of indigenously developed and manufactured bivalirudin in moderate/high-risk Indian patients undergoing percutaneous coronary intervention: the Bivaflo Registry.
Seth A; Sinha N; Parikh K; Patel T; Hiremath MS; Mehta AB; Chandra P; Pinto B; Sethi KK; Sengottuvelu S
Indian Heart J; 2008; 60(4):333-41. PubMed ID: 19242012
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
[TBL] [Abstract][Full Text] [Related]
18. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
Gurbel PA; Bliden KP; Saucedo JF; Suarez TA; DiChiara J; Antonino MJ; Mahla E; Singla A; Herzog WR; Bassi AK; Hennebry TA; Gesheff TB; Tantry US
J Am Coll Cardiol; 2009 Feb; 53(8):648-57. PubMed ID: 19232896
[TBL] [Abstract][Full Text] [Related]
19. Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Topol EJ
Am J Cardiol; 1998 Oct; 82(8B):63P-68P. PubMed ID: 9809894
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.
Cortese B; Micheli A; Picchi A; Bandinelli L; Brizi MG; Severi S; Limbruno U
Coron Artery Dis; 2009 Aug; 20(5):348-53. PubMed ID: 19543084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
